Topic Hub
12 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 12 of 12 clinical reviews.
Alendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, risks, and how it compares to on-label alternatives like risedronate and denosumab.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, and how it compares to other GIO treatments.
Read clinical reviewAlendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the dosing protocol, clinical trial evidence, guideline recommendations, and how it compares to FDA-approved alternatives.
Read clinical reviewAlendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Learn the GRADE-rated evidence, ACR guideline recommendations, dosing protocols, and monitoring requirements.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for male osteoporosis at 10 mg daily or 70 mg weekly. Learn the dosing protocol, key trial data, monitoring plan, and how it compares to other options for men.
Read clinical reviewA detailed evidence review of alendronate (Fosamax) for male osteoporosis, covering FDA approval status, key trial data, dosing, BMD outcomes, and fracture risk reduction in men.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for osteoporosis in postmenopausal women but used off-label in men. Review the clinical trial evidence, dosing, risks, and when a physician might prescribe it for male bone loss.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for male osteoporosis at 10 mg/day or 70 mg/week. This guide covers the evidence base, off-label nuances, dosing, and monitoring requirements for men on bisphosphonate therapy.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for Paget's disease at 40 mg daily for 6 months. Learn the full dosing protocol, monitoring targets, retreatment criteria, and how it compares to zoledronic acid and risedronate.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for Paget's disease of bone. This evidence summary covers dosing, trial data, guideline recommendations, and how it compares to other bisphosphonates for Paget's.
Read clinical reviewAlendronate (Fosamax) is used off-label for Paget's disease of bone. Review the clinical evidence, FDA-approved alternatives, dosing protocols, risks, and when clinicians choose this bisphosphonate over other options.
Read clinical reviewAlendronate (Fosamax) is used off-label for Paget's disease of bone. Learn about dosing, monitoring requirements, evidence quality, and how it compares to other bisphosphonates.
Read clinical review